By Maureen Testoni December 22, 2020– We are coming to the end of a year like no other in our memories. A worldwide pandemic has caused the deaths of more than 300,000 of our fellow Americans. An economic recession has forced businesses to close and millions of hard-working people to lose their jobs and their income – and for many their health insurance. An election … [Read more...]
Outcry Intensifies Over Pharma Moves Against 340B
September 10, 2020— Five major pharmaceutical companies are flouting the 340B drug pricing program statute, and others appear poised to follow suit. But a vocal group of safety-net providers and national organizations are calling on the federal government to use its authority to put a stop to those actions before patients are harmed. Beginning in late June, the drug makers … [Read more...]
No Fooling: Drug Maker 340B Price Transparency Has Improved
April 1, 2020– The first of April is an opportunity for people to play good-natured pranks on their family and friends. But this year it also gives hospitals participating in the 340B drug pricing program a chance to reflect on something that is definitely not a joke – drug manufacturer pricing transparency has improved because of a federal website that went live a year ago … [Read more...]
If It’s January, Drug Prices are Rising
January 8, 2020- There are few certainties in life, and the oft-quoted duo is death and taxes. But we can consider adding at least a third item to this list. In January, the prices of many already expensive prescription drugs will rise. The only question is: By how much? This week we began to learn about the pricing intentions of some of the major drug manufacturers in the … [Read more...]
Congressional 340B Champion Matsui Defends Program During Hill Hearing
October 18, 2019– Rep. Doris Matsui (D-Calif.), a longtime champion of the 340B drug pricing program, defended the program during a key congressional hearing to consider drug pricing legislation. Yesterday’s House Energy & Commerce Committee meeting to mark up the Lower Drug Costs Now Act of 2019 (H.R. 3) featured the introduction of an amendment that would have limited … [Read more...]
Drug Pricing Looms Large on Capitol Hill This Fall
September 9, 2019– Congress is back in town this week after the end of its August recess, and lawmakers are gearing up for a busy fall with a major focus on how to slow down ever-increasing drug prices. The cost of prescription drugs is on the minds of members from both parties in Congress as well as members of the Trump administration. Before they left town, two Senate … [Read more...]
340B May Curb High Drug Prices, New JAMA Study Finds
July 9, 2019– The 340B drug pricing program may discourage drug manufacturers from raising prices and instead may have the effect of reducing list prices for certain drugs. That’s according to a new study published in the Journal of the American Medical Association (JAMA). Study authors Sean Dickson of West Health and Ian Reynolds of the Pew Charitable Trusts evaluated the … [Read more...]